These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25845718)

  • 1. DEM analysis of the effect of particle-wall impact on the dispersion performance in carrier-based dry powder inhalers.
    Yang J; Wu CY; Adams M
    Int J Pharm; 2015 Jun; 487(1-2):32-8. PubMed ID: 25845718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-dimensional DEM-CFD analysis of air-flow-induced detachment of API particles from carrier particles in dry powder inhalers.
    Yang J; Wu CY; Adams M
    Acta Pharm Sin B; 2014 Feb; 4(1):52-9. PubMed ID: 26579364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-scale modelling of powder dispersion in a carrier-based inhalation system.
    Tong Z; Kamiya H; Yu A; Chan HK; Yang R
    Pharm Res; 2015 Jun; 32(6):2086-96. PubMed ID: 25511919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dry powders for oral inhalation free of lactose carrier particles.
    Healy AM; Amaro MI; Paluch KJ; Tajber L
    Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review.
    Tong Z; Yu A; Chan HK; Yang R
    Curr Pharm Des; 2015; 21(27):3966-73. PubMed ID: 26290194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particle-based coarse-grained approach for simulating dry powder inhaler.
    Liu X; Sulaiman M; Kolehmainen J; Ozel A; Sundaresan S
    Int J Pharm; 2021 Sep; 606():120821. PubMed ID: 34171427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CFD-DEM investigation of the effects of aperture size for a capsule-based dry powder inhaler.
    Zhu Q; Kakhi M; Jayasundara C; Walenga R; Behara SRB; Chan HK; Yang R
    Int J Pharm; 2023 Nov; 647():123556. PubMed ID: 37890648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.
    Le VN; Hoang Thi TH; Robins E; Flament MP
    AAPS PharmSciTech; 2012 Jun; 13(2):477-84. PubMed ID: 22399285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capsule-Based dry powder inhaler evaluation using CFD-DEM simulations and next generation impactor data.
    Almeida LC; Bharadwaj R; Eliahu A; Wassgren CR; Nagapudi K; Muliadi AR
    Eur J Pharm Sci; 2022 Aug; 175():106226. PubMed ID: 35643378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the mouthpiece and chamber of Turbuhaler® on the aerosolization of API-only powder formulations.
    Zhu Q; Gou D; Chan HK; Kourmatzis A; Yang R
    Int J Pharm; 2023 Apr; 637():122871. PubMed ID: 36948474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel dry powder inhalation system based on dispersion of lyophilisates.
    Claus S; Schoenbrodt T; Weiler C; Friess W
    Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating inter-patient variability of dispersion in dry powder inhalers using CFD-DEM simulations.
    Benque B; Khinast JG
    Eur J Pharm Sci; 2021 Jan; 156():105574. PubMed ID: 32980431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
    Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
    Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possibilities and advantages of additive manufacturing in dry powder formulations for inhalation.
    Wostry M; Scherließ R
    Eur J Pharm Sci; 2023 Nov; 190():106583. PubMed ID: 37703932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Powder dispersion mechanisms within a dry powder inhaler using microscale particle image velocimetry.
    Kou X; Wereley ST; Heng PW; Chan LW; Carvajal MT
    Int J Pharm; 2016 Dec; 514(2):445-455. PubMed ID: 27497998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.